EPCAM and cancer: The single-cell sequencing demonstrated that in the TME before the PMCT (May 14, 2019), TAMs accounted for a notable proportion (75.54%), followed by TILs (CD2+CD3D + TRBC2+; 11.96%), cancer cells (4.89%), and alveolar type II cells (AT2, EPCAM + SFTPC + SFTPB+; 4.89%) (Figures 4(b) and 4(c)).